Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

10.0%

1 terminated/withdrawn out of 10 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

30%

3 trials in Phase 3/4

Results Transparency

63%

5 of 8 completed trials have results

Key Signals

1 recruiting5 with results

Enrollment Performance

Analytics

Phase 1

4(40.0%)

Phase 2

3(30.0%)

Phase 3

3(30.0%)

10Total

Phase 1(4)

Phase 2(3)

Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT07215468Phase 2Recruiting

HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study

Role: lead

NCT05275998Phase 1Completed

TMB-365 and TMB-380 in Suppressed HIV-1 Infected Individuals

Role: lead

NCT03913195Phase 3Completed

Study of the Safety of Trogarzo™ Administered as an Undiluted "IV Push" or an Intramuscular Injection

Role: lead

NCT04027387Phase 1Completed

Dose Escalation Safety Study of TMB-365 in HIV-1 Infected Participants

Role: lead

NCT02707861Phase 3Completed

Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1

Role: lead

NCT03110549Phase 1Terminated

Study of the Safety, Tolerability and Pharmacokinetics of TMB-607 in HIV-Negative Volunteers

Role: lead

NCT02475629Phase 3Completed

Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV

Role: lead

NCT01056393Phase 2Completed

Investigator-Sponsored Protocol - Continued Use of Ibalizumab

Role: collaborator

NCT00784147Phase 2Completed

Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1

Role: lead

NCT01292174Phase 1Completed

Safety Study of Ibalizumab Subcutaneous Injection in Healthy Volunteers

Role: lead

All 10 trials loaded